Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections

Launched by INSTITUTO DO CANCER DO ESTADO DE SÃO PAULO · Oct 4, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at two different solutions, hyaluronic acid and hydroxyethylamide, to see which one works better during a specific type of surgery called endoscopic submucosal resection (ESD) for early-stage esophageal cancer. The goal is to determine which solution helps create a cushion in the tissue to make the surgery safer and more effective.

To participate in this study, adults over 18 years old who have been diagnosed with certain types of early esophageal cancer may be eligible. However, individuals with other serious health issues, certain types of esophageal lesions, or a history of allergic reactions to hyaluronic acid cannot take part. If you join the study, you’ll receive one of the two solutions during your procedure, and researchers will monitor your progress to see how well it works. This study is currently recruiting participants, so if you think you might qualify, it could be a chance to contribute to important medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age
• • Superficial esophageal adenocarcinoma or squamous cell carcinoma with indication of ESD after discussion in a multidisciplinary oncological board
• • Signed informed consent form
• Exclusion Criteria:
• • Residual or recurrent esophageal lesions
• • Ulcerated esophageal lesions
• • Patients with severe cardiovascular, kidney or liver disease
• • History of hypersensitivity to hyaluronic acid
• • Pregnant or lactating women